Jazz Pharmaceuticals PLC (JAZZ)
NASDAQ · Healthcare · Biotechnology
Jazz Pharmaceuticals PLC is a Healthcare company with a market capitalization of $14.45B and a trailing P/E ratio of 1,916.8.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 5, 2026 | $6.34 | $4.66 | +36.0% |
| Q4 2025 | February 24, 2026 | $6.64 | $6.51 | +2.1% |
| Q3 2025 | November 5, 2025 | $8.13 | $5.85 | +39.0% |
| Q2 2025 | August 5, 2025 | $-8.25 | $-6.25 | -32.0% |
| Q1 2025 | May 6, 2025 | $1.68 | $4.66 | -63.9% |
| Q4 2024 | February 25, 2025 | $6.60 | $5.81 | +13.6% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Jazz Pharmaceuticals PLC's market cap?
As of June 29, 2026, Jazz Pharmaceuticals PLC (JAZZ) has a market capitalization of $14.45B.
What is Jazz Pharmaceuticals PLC's P/E ratio?
Jazz Pharmaceuticals PLC trades at a trailing price-to-earnings (P/E) ratio of 1,916.8. Its forward P/E is 12.6.
Does Jazz Pharmaceuticals PLC pay a dividend?
Jazz Pharmaceuticals PLC does not currently pay a dividend.
What sector is JAZZ in?
Jazz Pharmaceuticals PLC is in the Healthcare sector, specifically the Biotechnology industry.
What was Jazz Pharmaceuticals PLC's revenue?
In its latest reported fiscal year (ending December 31, 2025), Jazz Pharmaceuticals PLC reported revenue of $4.27B and net income of -$356.15M.
Ask your own questions about JAZZ
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.